A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection

Abstract Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is closely associated with various malignancies. Considering the complex life cycle of EBV, developing vaccines targeting key entry glycoproteins to elicit robust and durable adaptive immune responses may provide better...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Miao Xu, Xiao Zhang
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-06-01
Online Access:	https://doi.org/10.1038/s41467-024-49546-w